ADPT
Adaptive Biotechnologies Corporation · Healthcare · Biotechnology
Momentum inputs (comparable managers):
holder breadth +22.2% ·
share flow +1.3% ·
net new positions +18.2%
— formula
Broad accumulation — rising shares across more holders
All ownership figures: tracked 13F managers only, common-stock positions, reporting period Q3 2024
| Quarter | Holders | Δ | Shares | Reported value | New | Exits |
|---|---|---|---|---|---|---|
| Q2 2026 | 107 | 0 | 115.06M | $2.46B | +6 | −6 |
| Q1 2026 | 110 | +7 | 111.61M | $1.55B | +11 | −4 |
| Q4 2025 | 102 | 0 | 114.72M | $1.86B | +1 | −1 |
| Q3 2025 | 21 | +2 | 74.70M | $1.12B | +2 | — |
| Q2 2025 | 16 | +2 | 70.34M | $819.50M | +2 | — |
| Q1 2025 | 11 | 0 | 46.91M | $348.49M | +2 | −2 |
| Q4 2024 | 11 | -1 | 53.01M | $317.80M | — | −1 |
| Q3 2024 | 11 | +2 | 55.08M | $282.02M | +2 | — |
| Q2 2024 | 9 | — | 54.39M | $196.88M | — | — |
| # | Manager | Shares | Δ shares | Value | Their weight | Held | ||
|---|---|---|---|---|---|---|---|---|
| 1 | Viking Global Investors ✦ | 29.99M | 0.0% | $153.57M | 0.6% | Held | 2 | SEC ↗ |
| 2 | ARK Investment Management ✦ | 11.60M | +1.7% | $59.40M | 0.5% | ▲ Add | 2 | SEC ↗ |
| 3 | Millennium Management ✦ | 9.40M | +1.5% | $48.13M | 0.0% | ▲ Add | 2 | SEC ↗ |
| 4 | Geode Capital Management ✦ (passive) | 2.66M | -0.8% | $13.63M | 0.0% | ▼ Trim | 2 | SEC ↗ |
| 5 | Geode Capital Management ✦ (passive) | 2.66M | -0.8% | $13.63M | 0.0% | ▼ Trim | 2 | SEC ↗ |
| 6 | Point72 Asset Management ✦ | 495.49K | New | $2.54M | 0.0% | New | 1 | SEC ↗ |
| 7 | AQR Capital Management ✦ | 261.96K | +43.9% | $1.34M | 0.0% | ▲ Add | 2 | SEC ↗ |
| 8 | AQR Capital Management ✦ | 261.96K | +43.9% | $1.34M | 0.0% | ▲ Add | 2 | SEC ↗ |
| 9 | AQR Capital Management ✦ | 261.96K | +43.9% | $1.34M | 0.0% | ▲ Add | 2 | SEC ↗ |
| 10 | Citadel Advisors ✦ | 209.43K | -47.9% | $1.07M | 0.0% | ▼ Trim | 2 | SEC ↗ |
| 11 | Citadel Advisors ✦ | 209.43K | -47.9% | $1.07M | 0.0% | ▼ Trim | 2 | SEC ↗ |
| 12 | Renaissance Technologies ✦ | 169.40K | +11.6% | $867,328 | 0.0% | ▲ Add | 2 | SEC ↗ |
| 13 | T. Rowe Price ✦ | 159.82K | +0.6% | $819,000 | 0.0% | ▲ Add | 2 | SEC ↗ |
| 14 | PRIMECAP Management ✦ | 76.03K | -48.0% | $389,274 | 0.0% | ▼ Trim | 2 | SEC ↗ |
| 15 | Two Sigma Investments ✦ | 52.36K | New | $268,083 | 0.0% | New | 1 | SEC ↗ |
“Their weight” = the position's share of that manager's reported 13F equity value — the conviction measure. ✦ = curated manager.
New buyers
| Point72 Asset Management | $2.54M | 0.0% |
| Two Sigma Investments | $268,083 | 0.0% |
Exited
| No tracked exits this quarter. |
Full-market context: across ALL 13F filers (SEC structured data, Q1 2026): 295 holders, 151.59M shares, $2.01B reported. This is a different, older period than the tracked-universe figures above and the two are never mixed.
What else this security's tracked holders most often hold — shared-ownership counts, not fundamental relationships.
Open-market purchases (P)
No open-market insider purchases in our coverage window.
Open-market sales (S)
Director · 15.00K sh · $365,850
Director · 15.66K sh · $382,358
Officer, Director · 278.47K sh · $6.82M
Officer, Director · 204 sh · $5,129
Officer, Director · 2.52K sh · $64,564
Director · 15.00K sh · $378,450
Director · 40.00K sh · $1.00M
Director · 69.69K sh · $1.75M
Officer, Director · 318.80K sh · $8.00M
Officer · 3.00K sh · $75,000
Awards, exercises and tax withholding are never counted as buys or sales here. Methodology